Traws Pharma (TRAW) insider granted RSUs and options on 12/12/2025 as equity awards

Rhea-AI Filing Summary

Traws Pharma director and chief operating officer Nikolay Savchuk reported new equity awards. On 12/12/2025, he received 16,419 restricted stock units of Traws Pharma common stock at $0, increasing his direct holdings to 150,606 shares.

The same day, he was granted stock options to buy 65,676 Traws Pharma shares at an exercise price of $2.33. Both the restricted stock units and the options vest 100% on the first anniversary of the 12/12/2025 grant date, providing additional long-term equity-based compensation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Savchuk Nikolay

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		16,419(1)	A	$0	150,606	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to purchase)	$2.33	12/12/2025		A		65,676		12/12/2026(2)	12/12/2035	Common Stock	65,676	$0	65,676	D

Explanation of Responses:

1. Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

2. The options vest 100% on the first anniversary of the grant date.

	/s/ Nikolay Savchuk	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Traws Pharma (TRAW) report in this Form 4?

The filing shows that Nikolay Savchuk, a director and chief operating officer of Traws Pharma, reported new equity awards consisting of restricted stock units and stock options granted on 12/12/2025.

How many Traws Pharma (TRAW) shares did the insider acquire through restricted stock units?

On 12/12/2025, the reporting person received 16,419 restricted stock units of Traws Pharma common stock at a price of $0 per unit.

What stock options were granted to the Traws Pharma (TRAW) insider and at what exercise price?

The insider was granted 65,676 stock options on 12/12/2025, each giving the right to purchase one share of Traws Pharma common stock at an exercise price of $2.33 per share.

When do the restricted stock units and options for Traws Pharma (TRAW) vest?

The filing states that the 16,419 restricted stock units and the 65,676 stock options each vest 100% on the first anniversary of the 12/12/2025 grant date.

How many Traws Pharma (TRAW) shares does the insider own after these transactions?

Following the reported transaction, the insider directly and beneficially owns 150,606 shares of Traws Pharma common stock, in addition to 65,676 stock options.

What is the expiration date of the Traws Pharma (TRAW) stock options granted in this filing?

The stock options granted on 12/12/2025 become exercisable on 12/12/2026 and have an expiration date of 12/12/2035, according to the filing.